GO
Loading...

Bristol-Myers Squibb Co

More

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • *MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.

  • March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • Cramer: Watch out for a big bounce in this sector Friday, 14 Mar 2014 | 10:17 AM ET

    CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.

  • Several insurers, including Molina Healthcare, which administer health plans for California's Medicaid program for the poor are asking states to step in and pay for Gilead Sciences Inc's Sovaldi, a drug that costs $84,000 per patient.

  • Follow-up from an early-stage, 107- patient trial of the drug, Bristol-Myers Squibb's nivolumab, found that a year after treatment, 62 percent of patients were alive. F. Stephen Hodi, director of the Melanoma Treatment Center at Boston's Dana-Farber Cancer Institute and one of the study's senior authors.

  • Pharma offering new hope for hepatitis C patients Wednesday, 26 Feb 2014 | 1:21 PM ET
    Hepatitis C virus

    New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.

  • Midday movers: Tesla Motors, Macy's, Target & More Tuesday, 25 Feb 2014 | 1:09 PM ET
    Tesla Model S

    Some of Tuesday's midday movers:

  • Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. The drugmaker had co-developed the drug with AstraZeneca.

  • FDA approves Bristol-Myers' drug for rare fat disorder Tuesday, 25 Feb 2014 | 9:07 AM ET

    Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The condition, known as generalized lipodystrophy, involves fat buildup in the blood and organs such as liver and muscle and can lead to diabetes, pancreatitis and fatty liver disease.

  • Feb 21- Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board.

  • Ariad to add two activist-backed directors to board Friday, 21 Feb 2014 | 7:55 AM ET

    Feb 21- Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board.

  • *Panel votes 7-2 against drug's use during a heart procedure. Feb 12- An independent advisory panel to the U.S. Food and Drug Administration said a blood clot preventer developed by The Medicines Co should not be approved due to a lack of data to prove its efficacy. Medicines Co shares fell 12 percent to $29.05 in post-market trading.

  • Feb 11- The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc's widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze XR.

  • Midday movers: Apple, Darden Restaurants & More Monday, 10 Feb 2014 | 12:22 PM ET

    Some of Monday's midday movers:

  • Feb 10- U.S. Food and Drug Administration reviewers are divided on whether an intravenous blood clot preventer developed by The Medicines Co should be approved, news that sent the company's stock down more than 7 percent on Monday.

  • *Q4 sales $6.84 bln vs consensus $6.88 bln. *Q4 core earnings per share $1.23 vs consensus $1.16. LONDON, Feb 6- AstraZeneca expects earnings to keep falling in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from late May.

  • *Q4 core earnings per share $1.23 vs $1.16. LONDON, Feb 6- AstraZeneca expects earnings to continue to fall in 2014 as generic competition to its popular heartburn and ulcer drug Nexium takes a big bite out of U.S. profits from May. Shares in AstraZeneca fell 1 percent in early trading.

  • Feb 4- Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.